New Search

If you are not happy with the results below please do another search

12 search results for:

2

Large Grant: “Neural Correlates of Impulsivity and their Modulation by Dopamine in Problem/Pathological Gambling”

Principal Investigator: Andrew Kayser, MD, PhD, University of California, San Francisco
Awarded $172,500 in 2013

Aim: Evaluate a novel translational (and potentially therapeutic) approach for gambling disorder: inhibitors of the dopamine-degrading enzyme catechol-O-methyltransferase (COMT). Several COMT-inhibitor drugs are already FDA-approved, and can be readily tested in human subjects.

4

Large Grant: “Efficacy of a Brief Motivational Intervention Delivered via Smartphone and Short Messaging Service”

Principal Investigator: Matthew Martens, PhD, University of Missouri, Columbia
Awarded $171,350 in 2013

Aim: Test the efficacy of a novel Brief Motivational Intervention (BMI) designed to reduce gambling among college students and delivered via smartphone devices (i.e., cell phones with comprehensive web applications) and Short Messaging Service (SMS) technology.

5

Early Stage Investigator Grant: “Developing a Mouse Model of Pathological Gambling using an Inducible and Tissue-specific Serotonin 1B Receptor Knock-out”

Principal Investigator: Katherine Nautiyal, PhD, Columbia University and Research Foundation for Mental Hygiene, Inc.
Awarded $147,706 in 2013

Aim: Determine the role played by the serotonin 1B receptor in the development of impulsive behavior through a mouse gambling behavioral model.

7

Seed Grant: “An Animal Model of Relapse to Pathological Gambling”

Principal Investigator: David Kearns, PhD, American University
Awarded $28,750 in 2013

Aim: Develop an animal model in which potential precipitators of relapse can be investigated. The animal model of relapse will not only provide information about the causes, but it will also set the stage for future research that tests behavioral and pharmacological interventions designed to prevent relapse.

9

Travel Grant: “The Atypical Antidepressant Mirtazapine Attenuates Gambling-like Behavior in Rodents”

Principal Investigator: Amanda Persons, PhD, Rush University Medical Center
Awarded $1,500 in 2013

The Travel Grant supported Dr. Person’s participation in the poster session at the 2013 meeting of the College on Problems of Drug Dependence (CPDD). She reported on research, funded by the NCRG, revealing that mirtazapine, an atypical antidepressant, reduced risk-taking behavior in rats.

10

Travel Grant: “Do Pathological Gamblers Suffer from a Distorted Sensitivity to Reward?”

Principal Investigator: Guillaume Sescousse, PhD, Donders Institute for Brain, Cognition and Behavior, the Netherlands
Awarded $1,500 in 2013

The Travel Grant supported Dr. Sescousee’s participation as a speaker at the 2013 meeting of the Society for Neuroscience. His research suggests a distorted sensitivity to reward in disordered gamblers. From a clinical perspective, the findings suggest that enhancing the prominence of non-monetary rewards may be a fruitful strategy as part of a therapeutic approach.